Friday, November 11, 2011

TC-5214 Depression Phase III Results

From Fierce Biotech:

Key AZ/Targacept depression drug flunks first Phase III test
By John Carroll
November 8, 2011 — 6:49am ET

[snippet]

"The high-profile depression drug TC-5214 has failed the first in a string of Phase III studies, dealing AstraZeneca's struggling R&D operation another stinging setback and walloping Targacept with a meltdown in its share value this morning."

[snippet]

Read the full article

Labels: ,

0 Comments:

Post a Comment

<< Home